Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine with or without nalbuphine for recovery quality after thyroidectomy
ChiCTR2500096415Phase 4Completed
- Sponsor
- The Second Affiliated Hospital of Shantou University Medical College
- Start
- Jan 2025
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of dexmedetomidine and nalbuphine in thyroid disease (3 arms), sponsored by The Second Affiliated Hospital of Shantou University Medical College. Primary endpoints: Incidence of agitation during the awakening period and Incidence of coughing during extubation. Started Jan 2025; status: completed.
02
Drugs
dexmedetomidinenalbuphine
03
Conditions
thyroid disease
Beyond the preview
Go deeper on ChiCTR2500096415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500096415.